1 / 61

Multidrug-Resistant Nosocomial Infections in the PICU : how to deal with it?

Multidrug-Resistant Nosocomial Infections in the PICU : how to deal with it?. Somchai Suntornlohanakul. Scope of Presentation. Introduction & Background of MDRO Epidemiology of MDRO MDRO prevention and control Preventing nosocomial infection in PICU: practical point for Nurse.

lorene
Télécharger la présentation

Multidrug-Resistant Nosocomial Infections in the PICU : how to deal with it?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Multidrug-Resistant Nosocomial Infections in the PICU : how to deal with it? Somchai Suntornlohanakul

  2. Scope of Presentation • Introduction & Background of MDRO • Epidemiology of MDRO • MDRO prevention and control • Preventing nosocomial infection in PICU: practical point for Nurse

  3. Multidrug-Resistant Nosocomial Infections in the PICU : how to deal with it? • Multidrug-resistant organisms (MDRO), including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and certain Gram-negative bacill (GNB) have important infection control implications • The prevention and control of MDRO is a national priority

  4. The prevention and control of MDRO is a national priority • The administration of healthcare organizations and institutions should ensure that • appropriate strategies are fully implemented • regularly evaluated for effectiveness • adjusted such that there is a consistent decrease in the incidence of targeted MDRO

  5. Successful prevention and control of MDRO Resources should include expert consultation, laboratory support, adherence monitoring, and data analysis Scientific Leadership Financial Support Administrative Leadership Human Resource Commitment

  6. Infection prevention and control professionals have found that healthcare personnel (HCP) are more receptive and adherent to the recommended control measures when organizational leadersparticipate in efforts to reduce MDRO transmission

  7. Multidrug-Resistant Organisms MDRO are defined as microorganisms, predominantly bacteria, that are resistant to one or more classes of antimicrobial agents. Although the names of certain MDRO describe resistance to only one agent (e.g., MRSA, VRE, [ESBL]-producing or intrinsically resistant Gram-negative bacilli), these pathogens are frequently resistant to most available antimicrobial agents

  8. Clinical importance of MDRO • In most instances, MDRO infections have clinical manifestations that are similar to infections caused by susceptible pathogens • Options for treating patients with these infections are often extremely limited • Increased lengths of stay, costs, and mortality also have been associated with MDRO

  9. MRSA and MSSA • MRSA may behave differently from other MDRO • MRSA colonized patients more frequently develop symptomatic infections • Higher case fatality rates have been observed for certain MRSA infections, including bacteremia, poststernotomy mediastinitis, and surgical site infections

  10. Epidemiology of MDRO • Prevalence of MDRO varies temporally, geographically, and by healthcare setting • The type and level of care also influence the prevalence of MDRO • Antimicrobial resistance rates are also strongly correlated with hospital size, tertiary-level care, and facility type

  11. Epidemiology of MDRO • Prevalence of target MDRO in the adult patient is greater than pediatric population. • Point prevalence surveys conducted by the Pediatric Prevention Network (PPN) in eight U.S. PICU and 7 U.S. NICU in 2000: • < 4% of patients were colonized with MRSA or VRE • 10-24% were colonized with ceftazidime- or aminoglycoside-resistant Gram-negative bacilli • < 3% were colonized with ESBL-producing Gram negative bacilli. • MDRO burden is greatest in adult hospital patients, but require similar control efforts

  12. Important concepts in transmission • Transmission and persistence of the resistant strain is determined by • the availability of vulnerable patients • selective pressure exerted by antimicrobial use • increased potential for transmission from larger numbers of colonized or infected patients (“colonization pressure”) • impact of implementation and adherence to prevention efforts

  13. Important concepts in transmission • Ample epidemiologic evidences suggest that MDRO are carried from one person to another via the hands of HCP • Without adherenceto recommendations for hand hygiene and glove use, HCP are more likely to transmit MDRO to patients • Strategies toincrease and monitor adherence are important components of MDRO control programs

  14. Role of colonized HCP in MDRO transmission • Rarely, HCP may introduce an MDRO into a patient care unit • Occasionally, HCP can become persistently colonized with an MDRO, but these HCP have a limited role in transmission, unless other factors are present. • Factors that can facilitate transmission, include chronic sinusitis, upper respiratory infection, and dermatitis

  15. MDRO Prevention and Control

  16. MDRO Prevention of Infections • Campaign to Reduce Antimicrobial Resistance in Healthcare Settings • A multifaceted, evidence-based approach with four parallel strategies: • infection prevention • accurate and prompt diagnosis and treatment • prudent use of antimicrobials • prevention of transmission

  17. Prevention and Control of MDRO transmission • Successful control of MDRO has been documented in the US and abroad using a variety of combined interventions • Hand hygiene • Contact Precautions • Active surveillance cultures (ASC) • Education • Enhanced environmental cleaning • Improvements in communication about patients with MDRO within and between healthcare facilities

  18. Control Interventions • Administrative support • MDRO Education • Judicious Antimicrobial Use • MDRO Surveillance • Infection Control Precautions to Prevent Transmission • Environmental Measures • Decolonization

  19. Administrative Support • Implementing systemchanges to ensure prompt and effective communications • Providing the necessary number and appropriate placement of hand washing sinks and alcohol-containing hand rub dispensers in the facility • Maintaining staffing levels appropriate to the intensity of care required

  20. Administrative Support • Enforcing adherence to recommended infection control practices for MDRO control • Adherence monitoring • Participation in regional or national coalitions to combat emerging or growing MDRO problems

  21. Control Interventions • Administrative support • MDRO Education • Judicious Antimicrobial Use • MDRO Surveillance • Infection Control Precautions to Prevent Transmission • Environmental Measures • Decolonization

  22. MDRO Education • Encourage a behavior change through improved understanding of the problem MDRO that the facility was trying to control • Facility-wide, unit-targeted, and informal, educational interventions • Patient outcomes • Antibiotic choice & Resistance • Infection control

  23. Control Interventions • Administrative support • MDRO Education • Judicious Antimicrobial Use • MDRO Surveillance • Infection Control Precautions to Prevent Transmission • Environmental Measures • Decolonization

  24. Pharmacokinetic (PK)/Pharmacodynamic (PD)considerations • The goal of antibiotic therapy is to achieve complete bacterial eradication and to minimise the risk of resistance selection • The dosing regimen is influenced by its PK profile and the susceptibility of the target pathogen • To predict bacteriological and clinical efficacy and help to identify the correct dose and dosing interval

  25. Judicious Antimicrobial Use • Focus on effective antimicrobial treatment of infections • Use of narrow spectrum agents • Treatment of infections and not contaminants • Avoiding excessive duration of therapy • Restricting use of broad-spectrum or more potent antimicrobials to treatment of serious infections when the pathogen is not known

  26. Strategies for influencing antimicrobial prescribing patterns • Education • Formulary restriction • Prior-approval programs • Automatic stop orders • Academic interventions to counteract pharmaceutical influences on prescribing patterns • Computer-assisted management programs • Active efforts to remove redundant antimicrobial combinations

  27. Control Interventions • Administrative support • MDRO Education • Judicious Antimicrobial Use • MDRO Surveillance • Infection Control Precautions to Prevent Transmission • Environmental Measures • Decolonization

  28. MDRO surveillance • Surveillance is a critically important component of any MDRO control program • allowing detection of newly emerging pathogens • monitoring epidemiologic trends • measuring the effectiveness of interventions • MDRO surveillance strategies • surveillance of clinical microbiology laboratory results obtained as part of routine clinical care • active surveillance cultures (ASC) to detect asymptomatic colonization

  29. 1: Surveillance for MDRO Isolated from routine clinical cultures 1.1 Antibiograms 1.2 MDRO Incidence Based on Clinical Culture Results 1.3 MDRO Infection Rates 1.4 Molecular typing of MDRO isolates

  30. 1.1 Antibiograms • Monitoring of clinical microbiology isolates resulting from tests ordered as part of routine clinical care • Detect emergence of new MDRO • Prepare facility- or unit-specific summary antimicrobial susceptibility reports that describe pathogen-specific prevalence of resistance among clinical isolates • Useful to monitor for changes in known resistance patterns • Provide clinicians with information to guide antimicrobial prescribing practices

  31. 1.2 MDRO Incidence Based on Clinical Culture Results • Calculate measures of incidence of MDRO isolates in specific populations or patient care locations (e.g. new MDRO isolates/1,000 patient days, new MDRO isolates per month) • Useful for monitoring MDRO trends and assessing the impact of prevention programs • Based solely on positive culture results without accompanying clinical information

  32. MDRO Incidence Based on Clinical Culture Results • Do not distinguish colonization from infection • Culture obtained from a patient several days after admission to a given unit or facility does not establish that the patient acquired colonization in that unit • Acquire MDRO colonization may remain undetected by clinical cultures

  33. MDRO Incidence Based on Clinical Culture Results • Despite limitations, incidence measures were highly correlated with actual MDRO transmission rates derived from information using ASC • The results suggest that incidence measures based on clinical cultures alone might be useful surrogates for monitoring changes in MDRO transmission rates

  34. 1.3 MDRO Infection Rates • Requires investigation of clinical circumstances surrounding a positive culture to distinguish colonization from infection • Can be particularly helpful in defining the clinical impact of MDRO within a facility

  35. 1.4 Molecular typing of MDRO isolates • Many investigators have used molecular typing of selected isolates to confirm clonal transmission to enhance understanding of MDRO transmission and the effect of interventions within their facility

  36. 2. Surveillance for MDRO by Detecting Asymptomatic Colonization • Active Surveillance Cultures (ASC) to identify patients who are colonized with a targeted MDRO • Based upon that, for some MDRO, detection of colonization may be delayed or missed completely if culture results obtained in the course of routine clinical care

  37. Use of ASC incorporated into MDRO prevention programs • Support for successful implementation includes • personnel to obtain the appropriate cultures • microbiology laboratory personnel to process the cultures • mechanism for communicating results to caregivers • concurrent decisions about use of additional isolation measures triggered by a positive culture (e.g. Contact Precautions) • mechanism for assuring adherence to the additional isolation measures

  38. Populations targeted for ASC • Not well defined • High risk for MDRO colonization based on • location (e.g. PICU with high MDRO rates) • antibiotic exposure history • presence of underlying diseases • prolonged duration of stay • exposure to other MDRO colonized patients • patients transferred from other facilities known to have a high prevalence of MDRO carriage, or having a history of recent hospital or nursing home stays • All patients admitted to units experiencing MDRO colonization

  39. Optimal timing and interval of ASC • Not well defined • Cultures were obtained at the time of admission to the hospital or intervention unit • Some obtain cultures on a periodic basis to detect silent transmission • Some based follow-up cultures on the presence of certain risk factors for MDRO colonization

  40. Methods for obtaining ASC • Must be carefully considered, and vary depending upon the MDRO of interest • MRSA: cultures of the nares, peri-rectal and wound cultures can identify additional carriers • VRE: Stool, rectal, or peri-rectal swabs • MDR-GNB: peri-rectal or rectal swabs alone or in combination with oro-pharyngeal, endotracheal, or wound cultures • The absence of standardized screening media for many Gram negative bacilli can make the process of isolating a specific MDR-GNB a relatively labor-intensive process

  41. Rapid detection methods • Using conventional culture methods can result in a delay of 2-3 days and the desired infection control measures could be delayed. • If empiric precautions are used pending negative surveillance culture results, precautions may be unnecessarily implemented.

  42. Control Interventions • Administrative support • MDRO Education • Judicious Antimicrobial Use • MDRO Surveillance • Infection Control Precautions to Prevent Transmission • Environmental Measures • Decolonization

  43. Infection Control Precautions • Standard Precautions • Contact Precautions • Cohorting and other MDRO control strategies • Duration of Contact Precautions • Impact of Contact Precautions on patient care and well-being

  44. Standard Precautions • An essential role in preventing MDRO transmission • Colonization with MDRO is frequently undetected • Standard Precautions must be used to prevent transmission from potentially colonized patients • Hand hygiene is an important component of Standard Precautions

  45. Contact Precautions • Prevent transmission of infectious agents transmitted by direct or indirect contact with the patient or the patient’s environment • A single-patient room is preferred • When a single-patient room is not available, consultation with infection control is necessary to assess the various risks associated with other patient placement options

  46. Contact Precautions • HCP should wear a gown and gloves for all interactions that may involve contact with the patient or potentially contaminated areas in the patient’s environment • Donning gown and gloves upon room entry and discarding before exiting the patient room is done

  47. Cohorting and other MDRO control strategies • Cohorting of patients • Cohorting of staff • Use of designated beds or units, unit closure were necessary to control transmission

  48. Duration of Contact Precautions • Remains an unresolved issue • In the context of an outbreak, prudence would dictate that Contact Precautions be used indefinitely for all previously infected and known colonized patients

  49. Duration of Contact Precautions • If ASC are used to detect and isolate patients colonized with MRSA or VRE • There is no decolonization of these patients • Contact Precautions would be used for the duration of stay in the setting where they were first implemented

More Related